Research presented at EAN 2020 suggests that lentiviral hematopoietic stem and progenitor cell gene therapy (HSPC-GT) may prevent or halt demyelination and brain atrophy in late infantile disease.
Research presented at EAN 2020 suggests that lentiviral hematopoietic stem and progenitor cell gene therapy (HSPC-GT) may prevent or halt demyelination and brain atrophy in late infantile disease.